Literature DB >> 15044590

Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3',5'-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways.

Kurt J Sales1, Stuart Maudsley, Henry N Jabbour.   

Abstract

Prostaglandin (PG) E(2) E-series prostanoid-2 (EP2) receptor is elevated in numerous carcinomas including the endometrium and has been implicated in mediating the effects of PGE(2) on vascular function. In this study, we investigated the intracellular signaling pathways that are activated by the EP2 receptor and their role in regulation of the expression of vascular endothelial growth factor in endometrial adenocarcinoma (Ishikawa) cells. Ishikawa cells were stably transfected with EP2 receptor cDNA in the sense or antisense directions. Treatment of Ishikawa cells with PGE(2) rapidly induced transactivation of the epidermal growth factor receptor (EGFR) and activation of ERK1/2 via the EP2 receptor. Preincubation of cells with chemical inhibitors of protein kinase A, c-Src, and EGFR kinase abolished the EP2-induced activation of EGFR and ERK1/2. PGE(2) signaling via the EP2 receptor also promoted the mRNA expression and secretion of vascular endothelial growth factor protein in Ishikawa cells. This effect was inhibited by preincubation with chemical inhibitors of EGFR kinase, ERK1/2 signaling, and small inhibitory RNA molecules targeted against the EGFR. Therefore, we have demonstrated that elevated EP2 receptor expression may facilitate the PGE(2)-induced release of proangiogenic factors in reproductive tumor cells via intracellular cAMP-mediated transactivation of the EGFR and ERK1/2 pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044590     DOI: 10.1210/me.2004-0022

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  27 in total

1.  Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells.

Authors:  Simone Kiermayer; Ricardo M Biondi; Jochen Imig; Guido Plotz; Jörg Haupenthal; Stefan Zeuzem; Albrecht Piiper
Journal:  Mol Biol Cell       Date:  2005-10-05       Impact factor: 4.138

Review 2.  Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Authors:  G O'Callaghan; A Houston
Journal:  Br J Pharmacol       Date:  2015-10-26       Impact factor: 8.739

3.  Transactivation of EGFR by prostaglandin E2 receptors: a nuclear story?

Authors:  Ana B Fernández-Martínez; Francisco J Lucio-Cazaña
Journal:  Cell Mol Life Sci       Date:  2014-12-17       Impact factor: 9.261

4.  Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.

Authors:  Daisuke Kamei; Makoto Murakami; Yuka Sasaki; Yoshihito Nakatani; Masataka Majima; Yukio Ishikawa; Toshiharu Ishii; Satoshi Uematsu; Shizuo Akira; Shuntaro Hara; Ichiro Kudo
Journal:  Biochem J       Date:  2009-12-23       Impact factor: 3.857

5.  Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear.

Authors:  Ryusuke Hori; Takayuki Nakagawa; Norio Yamamoto; Kiyomi Hamaguchi; Juichi Ito
Journal:  BMC Neurosci       Date:  2010-03-11       Impact factor: 3.288

6.  F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells.

Authors:  K J Sales; S C Boddy; H N Jabbour
Journal:  Oncogene       Date:  2007-10-29       Impact factor: 9.867

7.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

8.  Prokineticin 1 modulates IL-8 expression via the calcineurin/NFAT signaling pathway.

Authors:  David Maldonado-Pérez; Pamela Brown; Kevin Morgan; Robert P Millar; E Aubrey Thompson; Henry N Jabbour
Journal:  Biochim Biophys Acta       Date:  2009-04-05

9.  Prokineticin-1 (PROK1) modulates interleukin (IL)-11 expression via prokineticin receptor 1 (PROKR1) and the calcineurin/NFAT signalling pathway.

Authors:  Ian H Cook; Jemma Evans; David Maldonado-Pérez; Hilary O Critchley; Kurt J Sales; Henry N Jabbour
Journal:  Mol Hum Reprod       Date:  2009-10-03       Impact factor: 4.025

10.  EP2 receptor mediated cAMP release is augmented by PGF 2 alpha activation of the FP receptor via the calcium-calmodulin pathway.

Authors:  A B Abera; K J Sales; R D Catalano; A A Katz; H N Jabbour
Journal:  Cell Signal       Date:  2009-09-25       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.